1309P A genomic scar based signature (HRDsig) and biallelic BRCA alterations identify a homologous recombination deficiency (HRD) phenotype of non-small cell lung cancer (NSCLC) potentially actionable to the PARP inhibitor rucaparib: Post-hoc analysis of lung-MAP substudy S1900AJonathan W. Riess, Karen Kelly, Paul Wheatley‐Price et al.|Annals of Oncology|2024Cited by 2